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INTRODUCTION
Neurofibromatosis type 2 (NF2) is a dominantly 
inherited autosomal disease (affecting 1 in 30,000), 
attributed to the loss-of-heterozygosity (LOH) of the 
NF2 gene. The disease is characterized mainly by 
development of Schwann cell tumors of the eighth cranial 
nerve. Mutations and loss of heterozygosity (LOH) of the 
NF2 locus have also been detected at high frequency in 
various tumors of the nervous system, including sporadic 
schwannomas, meningiomas and ependymomas [1]. The 
NF2 tumor suppressor gene encodes a 69-kDa protein 
called Merlin (Moesin, ezrin, and radixin like protein), 
implicated in the regulation of a number of the Rac1, 
Ras/MAPK, mTOR and Hippo signaling pathways [2]. 
Previous studies have demonstrated that Merlin interacts 
with CD44 and inhibits signaling through the MET 
proto-oncogene, a receptor tyrosine kinase [3]. In 
addition, analysis of NF2-null vestibular schwannomas 
demonstrated dysregulation of MET expression and 
other associated genes [4]. Moreover, several studies 
have demonstrated that Merlin functions as an inhibitor 
of the group I p21-activated kinases (PAKs), by direct 
inhibition and by inhibition of the small G-protein Rac1, 
a direct upstream activator of the PAKs [5–8]. Previous 
studies have shown that the p21-activated kinase 1 
(PAK1) activates MET signaling and that disruption of 
this activity inhibits PAK1-driven anchorage-independent 
cell growth [9]. This is especially significant in the case 
of NF2, as previous work has established the PAKs as 
necessary effectors and targets for inhibition in NF2 
[6, 10]. These findings implicate MET as a potential target 
for therapeutic inhibition in the context of NF2 loss. We 
therefore set out to determine whether MET inhibition 
would be beneficial in a model of NF2-associated 
schwannoma. 
Towards this goal we employed pharmacologic 
and genetic approaches to inhibit MET and identified the 
FDA approved drug crizotinib (PF-2341066), as a potent 
inhibitor of tumor progression and cellular proliferation of 
NF2-null Schwann cells. Moreover, our studies establish 
the inhibition of FAK1  (PTK2) as the primary mechanism 
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ABSTRACT
Neurofibromatosis type 2 (NF2) is a dominantly inherited autosomal disease 
characterized by schwannomas of the 8th cranial nerve. The NF2 tumor suppressor 
gene encodes for Merlin, a protein implicated as a suppressor of multiple cellular 
signaling pathways. To identify potential drug targets in NF2-associated malignancies 
we assessed the consequences of inhibiting the tyrosine kinase receptor MET. We 
identified crizotinib, a MET and ALK inhibitor, as a potent inhibitor of NF2-null Schwann 
cell proliferation in vitro and tumor growth in vivo. To identify the target/s of crizotnib 
we employed activity-based protein profiling (ABPP), leading to identification of 
FAK1  (PTK2) as the relevant target of crizotinib inhibition in NF2-null schwannoma 
cells. Subsequent studies confirm that inhibition of FAK1  is sufficient to suppress 
tumorigenesis in animal models of NF2 and that crizotinib-resistant forms of FAK1  
can rescue the effects of treatment. These studies identify a FDA approved drug as 
a potential treatment for NF2 and delineate the mechanism of action in NF2-null 
Schwann cells.
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of action for crizotinib in these cells. As crizotinib is well 
tolerated and is currently being evaluated in clinical trials 
in pediatric settings, our findings provide a strong rationale 
for assessing this drug in NF2 patients.
RESULTS 
Crizotinib inhibits schwannoma cell 
proliferation and tumor formation in vivo 
As previous studies implicated signaling downstream 
of MET as a potential therapeutic target in vestibular 
schwannoma [3, 4], we assessed the consequences of 
inhibiting MET in NF2-null Schwann cells. HEI193 
cells (NF2-null, derived from a schwannoma of an NF2 
patient), SC4 cells (Nf2-null mouse cells) and hSC2l-
shNF2 cells (hSC2l cells – immortalized normal human 
Schwann cells with stable knockdown of NF2) were 
treated with crizotinib (PF-2341066), a FDA approved 
drug that is a potent inhibitor of MET, ALK and Ros-1 
[11]. Treatment of these cells resulted in a dose-dependent 
reduction in cell numbers over a period of 72 hours 
(Figure 1A–1C). To more accurately assess the inhibitory 
activity of crizotinib, we performed dose-response 
studies and established the EC
50
s as 54 nM and 230 nM 
in SC4 or HEI193 cells, respectively (Figure 1D–1E). 
To determine if the effects of crizotinib are due to 
reduced cell proliferation or increased cell death rates, we 
assessed BrdU incorporation in treated SC4 cells.  BrdU 
incorporation was significantly reduced over 72-hours, 
indicating that crizotinib has a strong effect on cellular 
proliferation (Figure 1F). To assess the potential effects 
of crizotinib on cell death, we examined the status of a 
number of apoptotic markers in the treated cells. We did 
not observe any differences in levels of cleaved Caspase-3, 
Caspase-7 and PARP between SC4 cells treated with 
crizotinib or vehicle only (not shown). These data suggest 
the effects of crizotinib are mediated primarily through 
inhibition of cell proliferation. 
To assess if crizotinib can inhibit tumor growth 
in vivo, we employed an orthotopic model of NF2 
that recapitulates the tumor microenvironment of 
schwannomas, by injection of luciferase-tagged NF2-null 
SC4 cells into a myelinated nerve [12, 13]. In this 
model, tumors are first allowed to form and only then 
treatment is commenced. Beginning at 3 days post 
surgery, tumor progression was monitored every three 
days by bioluminescence imaging (BLI) and total flux 
counts were recorded for each animal. Ten days post 
injection, similar flux readings for all animals were 
validated and animals were then enrolled randomly 
into control (vehicle only) or drug-treated cohorts and 
were treated (100 mg/kg, IP, once daily) for a period 
of 24 days. Analysis of the flux reading for the animals 
in the cohorts indicated the trends of tumor growth are 
significantly different between the cohorts and that 
crizotinib treated mice displayed a significantly slower 
tumor growth rate (Figure 2A–2B). After 24 days of 
treatment the animals were sacrificed and the tumors 
removed and weighed. Comparison of the cohorts 
demonstrates a significantly lower average tumor weight 
in the crizotinib-treated group compared to control group 
(Figure 2C). Taken together, these data demonstrate 
that crizotinib has significant anti-proliferative activity 
against NF2-null Schwann cells in vitro and anti-tumor 
activity in vivo.
MET is dispensable for NF2-null schwann cell 
proliferation
To determine whether the effects of crizotinib 
are mediated through inhibition of MET, we employed 
pharmacological and genetic approaches to target MET 
more precisely. HEI193 or SC4 cells were treated with 
capmatinib (INC280), a potent MET inhibitor with 
reported average IC
50
 of 0.13 nmol/L. INC280 is highly 
selective towards MET and at 2 μmol/L exhibited 30% or 
less inhibition against a panel of 57 structurally diverse 
kinases [14]. Treatment of SC4 or HEI193 cells with doses 
of up to 10 mM and up to 72 hours had negligible effects 
on the proliferation of treated cells compared to controls 
(Supplementary Figure S1A–1B). To assess the requirement 
for MET directly, genome editing using the CRISPR/
Cas9 system was used to inactivate both MET alleles in 
SC4 cells, generating SC4MET(−) cells (Supplementary 
Figure S1C). Inactivation of MET had a minimal effect on 
the proliferation of SC4MET(−)  cells compared to controls 
(Supplementary Figure S1D). Similar results were obtained 
using 2 independent siRNA oligos to knockdown the 
expression of MET (Not shown).  Finally, treatment of 
SC4MET(−) cells with crizotinib resulted in nearly identical 
activity compared to SC4 cells, suggesting the activity 
of crizotinib was not mediated through MET inhibition 
(Supplementary Figure S1D). 
Crizotinib inhibits a broad spectrum of kinases 
in NF2-null schwannoma cells 
As the anti-proliferative effects of crizotinib on 
SC4 and HEI193 do not appear to be mediated through 
inhibition of MET, we applied a combination of unbiased 
approaches to identify the relevant targets. First, 
we examined the expression of kinases in SC4 cells 
through unbiased RNA sequencing (RNA-Seq) reads. 
The normalized read-counts of all annotated kinases 
revealed a broad pattern of expression of kinases from 
all families. Interestingly, the typical targets of crizotinib 
ALK and Ros-1 do not appear to be expressed in SC4 
cells (Figure 3A and Supplementary Table S1). Western 
blot analysis of protein extracts from SC4 and HEI193 
to assess the expression of ALK and Ros-1 confirmed 
the lack of expression (not shown). To identify the 
kinases inhibited by crizotinib we employed activity-
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based protein profiling (ABPP). Briefly, we used an 
affinity column composed of multiple kinase inhibitors 
conjugated to Sepharose beads. This Multiplexed 
Inhibitor Bead (MIB) matrix provides the capability to 
capture > 85% of known protein kinases. The kinases 
were then eluted from the MIB matrix and identified and 
quantitated by mass spectrometry. This approach allowed 
us to compare multiple samples in a single run [15, 16]. 
Comparison of the kinases captured by the MIB matrix 
to the RNA-seq expression data indicates the matrix 
captured the vast majority of kinases expressed (at least 
at the transcriptional level) in the SC4 cells (Figure 3B). 
We next treated SC4 cells with crizotinib and 
collected cells at 0′, 30′, 240′ and 24 hours post treatment. 
Protein extracts from the different time points were 
analyzed by ABPP, as described above, and levels of 
captured kinases were assessed over time. The binding to 
crizotinib should prevent binding of an inhibited kinase to 
the MIB matrix and therefore levels of the kinase in treated 
fractions will be decreased (Supplementary Table S2). 
We applied the following criteria to identify targets of 
crizotinib that might mediate the effects observed in SC4 
cells: First, target displays > 2 fold reduction relative to 
untreated cells and, second, the reduction is sustained up 
to 24 hours. Applying these selection criteria resulted in 
the identification of 10 kinases: NUAK1, NDKM, PLK4, 
TESK1, ATR, SLK, PTK2, PTK2B, EPHA2 and STK10 
(Figure 3C).
Crizotinib’s anti- proliferative activity is 
mediated by inhibition of FAK1/PTK2 
Although the ABPP identified at least ten potential 
candidates for crizotinib’s activity, given the previous 
reports correlating NF2 deficiency to sensitivity of 
FAK1 inhibition [17, 18] we focused initially on FAK1 
as the potential relevant crizotinib target in NF2-null 
schwannoma cells. To confirm that indeed crizotinib 
inhibits FAK1 in SC4 and HEI193 cells we treated the cells 
and assessed FAK1 activation by western blot analysis 
using a phospho-specific antibody against FAK-Y397, 
which is phosphorylated in activated FAK1. As expected, 
treatment with crizotinib resulted in decreased FAK-Y397 
phosphorylation indicating it inhibits the activation of 
FAK1 in these cells (Figure 4A). To determine if FAK1 
is required for proliferation of SC4 or HEI193 cells we 
employed shRNA or siRNA, respectively, to knockdown 
expression of FAK1 in these cells. Indeed, the knockdown 
of FAK1 significantly impaired the proliferation of these 
cells (Figure 4B–4C). In addition, we examined the effects 
of treating SC4 or HEI193 cells with small-molecule 
FAK1 inhibitors. Treatment of SC4 or HEI193 cells with 
defactinib (VS6303) or PND-1186 (VS-4718) significantly 
impaired cell proliferation in a dose-dependent manner 
(Figure 4D and not shown). 
As the loss of function studies demonstrated 
crizotinib inhibits FAK1 in NF2-null Schwann cells 
Figure 1: Impact of crizotinib treatment on NF2-null schwann cell proliferation. (A) SC4, (B) HEI193 or (C) hSC2l-shNF2 
cells treated with crizotinib at the indicated concentrations or with 25% DMSO control, daily for 3 days. (D–E) 10-point dose response 
curves assessing viability of SC4 or HEI193 cells treated with Crizotinib at the indicated concentrations. (F) The proliferation of SC4 cells 
was assessed by BrdU incorporation at 24, 48 and 72 hours post crizotinib treatment (1 mM) compared to control (DMSO). In all counting 
experiments cell numbers were scored daily and each time point was done in triplicate. The data shown is the mean of 3 independent 
experiments. Error bars = SD. 
Oncotarget54518www.impactjournals.com/oncotarget
and is required for the proliferation of these cells, we 
sought to confirm these observations through gain of 
function approaches. Towards this aim, we first identified 
ALK mutations previously shown to confer a decreased 
sensitivity to crizotinib and assessed their conservation 
in FAK1. Mutations at residue S1206, located at the 
solvent front of the kinase domain, and at G1269, located 
in proximity to the DFG motif, have been suggested to 
diminish the affinity of ALK to crizotinib and facilitate 
cell survival in response to treatment [19, 20]. Both 
S1206 and G1269 are located in regions of ALK that are 
highly conserved in FAK1 with the equivalent residues 
at Serine 509 and Glycine 563, respectively (Figure 5A). 
We thus generated stable SC4 cells expressing FAK1wt, 
FAK1S509R, FAK1G563S and FAK1S509R/G563S and assessed 
the expression levels and activity of the different FAK1 
alleles. The expression levels of FAK1 are similar for 
the wild type and mutated alleles as are the levels of 
activation, as determined by phosphorylation of the 
Y397 autophosphorylation site (Figure 5B). To determine 
whether the mutated alleles confer resistance to crizotinib 
we assessed the EC
50
s for SC4 cells stably expressing 
the different alleles. In a similar manner to what has 
been previously reported for ALK, the FAK1 S509R, 
G563S and S509R/G563S alleles conferred resistance to 
crizotinib treatment. While expression of wild type FAK1 
increased the EC
50
 by 2-fold, the expression of the mutated 
FAK1 alleles shifted the EC
50
 by an order of magnitude 
(Figure 5C). Thus, the results from both loss- and gain-of-
function experiments strongly implicate FAK1 inhibition 
as the main mechanism through which crizotinib mediates 
its effects in NF2-null schwannoma cells.
DISCUSSION 
In spite of more than 2 decades of research 
into the molecular basis of NF2, treatment options 
are still lacking. Current treatment options are anti-
symptomatic, are limited to radiation or surgery 
and associated with severe morbidity. In an effort 
Figure 2: Crizotinib inhibits tumor growth in vivo. (A) Representative images from bioluminescence imaging (BLI) of mice 
carrying orthotopic tumors treated with crizotinib (50 mg/kg) or vehicle control (25% DMSO) at day 14 of treatment. NOD/SCID mice 
were injected intraneurally with 5 × 104 SC4/pLuc-mCherry cells and were enrolled into treatment after 10 days. Mice were treated daily 
for 25 days and imaged every 3 days to follow tumor development. (B) Quantitative analysis of the flux reading from treated cohorts. A 
mixed-effect model analysis indicated that the speed of tumor growth in treatment group is significantly slower than that in control group 
(p = 0.003). (C) Distribution of tumor/body weight ratio in the cohorts treated with crizotinib or vehicle control. The results of t-test with 
equal variances show that the crizotinib-treated group has significant lower average tumor weight than that observed in control group 
(p < 0.0001). For the in vivo experiments the N = 9 in each cohort.
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to identify suitable therapeutic targets, we initially 
focused on the MET tyrosine kinase inhibitor, based 
on previous reports implicating it as a potential target 
[3, 4, 9]. While our findings indicate MET is mostly 
dispensable for the proliferation of NF2-null Schwann 
cells, our efforts identified crizotinib (Xalkori®- Pfizer) 
as a having significant anti-proliferative activity both 
in vitro and in vivo. Crizotinib was developed as an ATP-
competitive inhibitor of the anaplastic lymphoma kinase 
(ALK) and the MET/hepatocyte growth factor receptor 
(HGFR) [11, 21]. However, it has been shown to bind and 
inhibit multiple additional targets including the ROS1 and 
RON receptor tyrosine kinases [22–24]. 
As the primary targets of crizotinib inhibition do 
not appear to be expressed in NF2-null Schwann cells, 
we employed ABPP to identify 10 kinases that appear 
to be significantly inhibited by crizotinib.  Although 
it is possible that any of these kinases, either alone or 
in combination, represents the target through which 
crizotinib mediates its anti-tumor effects, the recently 
reported association between NF2-status and sensitivity 
to FAK1 inhibition (see below) led us to focus on FAK1 
as the potential target. Moreover, previous reports using 
competition binding approaches to assess inhibitor 
selectivity/potency have identified crizotinib as a potent 
inhibitor of FAK1 ([22] and HMS Library of Integrated 
Network-based Cellular Signatures PF02341066 
KINOMEscan dataset 20033). Multiple lines of evidence 
from our work suggest that FAK1 is indeed the relevant 
target of crizotinib. First, our data confirm that crizotinib 
treatment inhibits the activation of FAK1, as determined 
by phosphorylation of tyrosine 397 which correlates with 
activation of this kinase [25, 26]. Second, treatment of 
NF2-null Schwann cells with small molecules inhibitors 
of FAK1 result in inhibition of cell proliferation in a dose-
dependent manner, mimicking the outcomes of crizotinib 
treatment. Third, and most important, direct inhibition of 
FAK1 in two NF2-null Schwann cell lines, using siRNA 
or shRNA, recapitulates the phenotypes observed with 
crizotinib treatment and confirms that loss of FAK1 is 
incompatible with proliferation of these cells. Finally, the 
ability of crizotinib resistant FAK1 mutants to shift and 
increase the EC
50
 of crizotinib against SC4 cells suggests 
that the effects of crizotinib in these cells are mediated 
largely through FAK1 inhibition. While these studies do 
not exclude the possible contribution of other targets, 
Figure 3: Expression and activity based profiling of the kinome in NF2-null schwann cells. (A) Untreated SC4 cells were 
extracted for RNA and analyzed by sequencing. The expressed kinases ( > 1 RPKM) are indicated in yellow on the dendogram, with the 
size of each circle representing the log
2
 transformed RPKM value. (B) Untreated SC4 cells were extracted for protein and the activity-based 
profile of the kinome was assessed by binding to a multiplexed inhibitor bead matrix, followed by elution of bound proteins and identification/
quantification by label-free mass spectrometry. The levels of each kinase identified are indicated in red on the dendogram, with the size 
of each circle representing the log
2
 transformed quantification value. (C) Time-dependent activity-based profiles for kinases that met the 
selection criteria. SC4 cells were treated with 10 mM crizotinib and harvested at 0, 30′, 4 h and 24 h post treatment. LFQ = Label-Free 
quantification values.
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the extent and concordance of the phenotypes observed 
suggest that inhibition of FAK1 is the major mechanism 
through which the effects of crizotinib are mediated.
FAK1  (coded by the PTK2 gene) is a cytoplasmic 
tyrosine kinase shown to be upregulated and activated 
in a range of solid tumor types. FAK1 promotes cell 
proliferation, survival, motility and other functions, 
through kinase-dependent and independent mechanisms 
[27]. Recent studies in a panel of mesothelioma cells lines 
revealed that sensitivity to FAK1 inhibition was inversely-
correlated to levels of Merlin expression. The proposed 
mechanism suggests Merlin loss leads to destabilization 
of cell:cell junctions, which causes the cells to become 
more reliant on cell-ECM interactions for survival and 
proliferation. As FAK1 is a critical effector of these 
proliferative/survival signals, the consequences of FAK1 
inhibition in the context of NF2 loss are detrimental to 
the cells [18]. Other studies examining the relationship 
between Merlin and FAK1 in ovarian cancer cell identified 
a correlation between Merlin expression levels and 
sensitivity to FAK1 inhibitors, when cells were grown in 
an anchorage-independent manner. Intriguingly, stable 
knockdown of Merlin in resistant cells did not sensitize 
cells to FAK1 inhibition. This suggests that at least in 
ovarian cancer cell lines Merlin expression might predict 
responsiveness to FAK1 inhibitors, although a causal link 
between Merlin and FAK1 was not identified [17]. These 
recent findings, along with the data presented in our report, 
Figure 4: FAK1 is inhibited by crizotinib and required for proliferation of NF2-null schwann cells. (A) Western blot 
analysis of total FAK1 and p-FAKY397 in protein extracts prepared from SC4 and HEI193 cells treated with crizotinib (10 μM for 10′ and 30′). 
Vinculin was used as a loading control. (B) Cell number counts of SC4 cells and western blot analysis of total FAK1 expression in cells 
treated with 2 independent shRNAs against FAK1 (shFAK-a, shFAK-b) or scrambled control (shCTRL). (C) Cell number counts of HEI193 
cells and western blot analysis of total FAK1 expression in cells treated with 2 independent shRNAs against FAK1 (siFAK-a, siFAK-b) or 
scrambled control (siCTRL). (D) SC4 or HEI193 cells treated with defactinib at the indicated doses or with DMSO control, daily for 3 days. 
In all counting experiments cell numbers were scored daily and each time point was done in triplicate. The data shown represent the mean 
of 3 independent experiments. Error bars = SD.
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strongly implicate FAK1 as a critical effector and as a 
relevant target in the context of Merlin deficiency. 
From a clinical standpoint, crizotinib represents an 
excellent candidate for evaluation in NF2. It is well tolerated 
and has already received FDA approval for the treatment of 
patients with metastatic non-small cell lung cancer that are 
positive for activating ALK fusions. In addition, crizotinib is 
being evaluated in phase I/II trials in children with relapsed/
refractory solid tumors and primary CNS tumors such as 
neuroblastoma (NCT00939770). In addition to assessing the 
efficacy of crizotinib against NF2-deficient schwannomas, 
the activity of crizotinib against other NF2-null tumors, such 
as meningiomas and mesotheliomas, should be evaluated. 
While crizotinib was developed as an MET/ALK inhibitor, 
there are a number of inhibitors specifically developed 
against FAK1 that are currently in various stages of clinical 
trial. These include GSK2256098, PND-1186 (VS-4718), 
PF-271 (VS-6062) and defactinib (VS-6063) [27]. Once 
approved, these drugs could represent additional therapeutic 
options for NF2-null tumors and should thus be evaluated. 
Interestingly, our studies with PND-1186 and defactinib 
suggest a similar potency of these drugs compared to 
crizotinib. This suggests that the inhibitory capacity of 
crizotinib against FAK1 is sufficient to elicit a favorable 
effect. However, a true comparison of these drugs will 
ultimately require assessment in a clinical trial setting.
In summary, our studies identify an FDA approved 
drug, crizotinib, which shows in vitro and in vivo efficacy 
against NF2-null schwannomas. Furthermore, our studies 
identify the mechanism of action, through the inhibition of 
FAK1. Given the lack of curative options for NF2 and the 
favorable tolerability of this drug, crizotinib represents an 
excellent candidate for clinical testing in patients harboring 
NF2-deficient tumors.
Figure 5: Crizotinib-resistant FAK1 mutants rescue proliferation of treated NF2-null schwann cells. (A) Superimposition 
of the FAK1 (orange) and ALK (gray) kinase domains with crizotinib (ball and stick). Residues Glycine 509 (G509) and Serine 563 (S563) 
are highlighted (ball and stick). (B) Western blot analysis of the different FAK1 mutant expression in stably transfected SC4 cells. Vinculin 
was used as a loading control (C) 10-point dose response curves assessing EC50 of crizotinib in SC4 cells stably expressing crizotinib 
resistant FAK1 mutants. Calculated EC50 for each clone is indicated to the right. The data shown represents the mean of 3 independent 




The SC4 and HEI193 cell lines were obtained 
from The House Ear Institute and ATCC, respectively. 
The hSC2l cells are a gift from Dr. Margaret Wallace 
(U. of Florida) [28]. All cell lines were authenticated 
by short tandem repeat (STR) DNA profiling (DDC 
Medical) (March 2015) and verified to be clean of 
mycoplasma contamination using a PCR based approach. 
Cells were grown in low-glucose DME, 10% fetal calf 
serum, 1× non-essential amino acids and 100 IU/ml 
penicillin-streptomycin. Transfections were performed 
with Lipofectamine 2000 (Invitrogen), following 
manufacturer’s instructions. 
Western blot analysis
Protein extracts were prepared with RIPA lysis 
buffer (50 mM TRIS-HCl, pH 7.5, 1% Nonidet P-40, 
0.25% sodium deoxycholate, 150 mM NaCl, 1 mM 
EGTA, 1 mM sodium orthovanadate, and 1 mM NaF). The 
following antibodies were used according to manufactures’ 
instructions: MET, FAK1  and FAK-pY397 (cat# 3127, 
3285, 3283 - Cell Signaling Technology).
RNAi-mediated knockdown of FAK
HEI193 and SC4 cells were transfected using 
Lipofectamine 2000 (Invitrogen, NY, USA), according to 
the manufacturer’s instructions. Specifically HEI193 cells 
were transfected with siRNA duplexes targeting FAK1 
[ID# SR303877A- GCAAUGGAGCCGAGUAUUA 
AAGGUCT and SR303877B- AGAAGAUACUUACA 
CCAUGCCCUCA] as well as a non-targeting siRNA 
 control [ID # SR30004- CGUUAAUCGCGUAUAAUACG 
CGUAT] (Origene, Rockville, USA) at a concentration 
of 30 nM. SC4 cells were transfected with TRC mouse 
 shRNA individual clones targeting FAK1  [ID # TRCN0000 
023484 -5′-CGGTCCAATGACAAGGTATAT-3′ and 
TRCN0000023486–5′-CCAACCTTAATAGAGAAGAA 
A-3′] (GE Dharmacon, Lafayette, USA). 
CRISPR/Cas9 editing of MET
Guide sequences from exon 1 of the MET locus 
(g#1- GTTTACTGACATACGCGGCT and g#2- 
GTTCATCTCAGACTTCACTA) were cloned into the 
pX459 vector (Addgene). SC4 cells were transfected with 
8 mg of plasmid into the SC4 cells using Lipofectamine 
2000, according to manufacturer’s instructions. Cells 
were selected for 48 hours in puromycin and individual 
clones were picked and expanded after 7 days. Clones 
were analyzed by western blotting to determine loss of 
MET expression. 
Cell proliferation assays
30,000 cells/well were plated in 12-well dishes in 
triplicate. At indicated time points, cells from individual 
wells were trypsinized and counted using a Coulter 
counter (Z1 series, Beckman Coulter). Cell growth media 
was replaced daily. For measurement of cell proliferation, 
cells were plated at the numbers indicated in the figures 
and BrdU Proliferation Assay (Millipore) was used 
according to the manufacturer’s instructions. Statistical 
significance was determined by a two-tailed student’s 
t-test. Each condition at each time point represents the 
mean of 3 experiments in triplicate for a total of 9 wells.
Generation of FAK1  mutants and stable SC4 
clones
The FAK1  mutant constructs were created by PCR 
amplification of FAK1  cDNA from the pLV-Neo-CD2-
FAK1 (addgene #37013) and cloning into pcDNA3.1 
using NheI and NotI sites (primer sequences Fak-Nhe1F 
5′-aaaagctagcaaaATGGCAGCTGCTTACCTTGACC-3′, 
Fak-Not1R 5′-aaaagcggccgcaaaTCAGTGTGGTCTCG 
TCTGCC-3′). Site directed mutagenesis was 
performed using the Agilent Quick Change Site-
Directed Mutagenesis Kit (cat# 200518-5).  Primers 
were designed using the SDM design tool on the 
Agilent website. Primer sequences: FAKS509R: 
5′-gcacacttggagagctgaggagatttttgcaagtaaggaaat-3′ and 
5′-atttccttacttgcaaaaatctcctcagctctccaagtgtgc- 3′. FAKG563S: 
5′ –ctggtgtcctcaaatgattgtgtaaaattaagcgactttggattatccc-3′ and 
5′- gggataatccaaagtcgcttaattttacacaatcatttgaggacaccag-3′. 
Bacterial clones were isolated and sequence verified.  SC4 
Cells were transfected with 8 μg of plasmid DNA, using 
Lipofectamine 2000 (cat# 11668019), and were placed under 
G418 selection, 150 ug/ml until individual clones could be 
picked and expanded for experimentation.
RNA sequencing data
RNA from SC4 cells was extracted using TRIZOL 
reagent. 5–10 μg of total RNA was used to isolate poly(A) 
RNA using the micropoly(A) purist kit (Ambion). The 
whole transcriptome library kit (Life Technologies) was 
used to prepare paired-end sequencing libraries. Briefly, 
100 ng of poly(A)+ RNA was enzymatically fragmented 
to an average size of 150 nt, ligated to directional adapters 
and reverse-transcribed, and the cDNA was size-selected 
on denaturing 6% TBE-Urea polyacrylamide gels, 
amplified for 15 cycles with barcoded primers and purified 
using AmpPure XP beads. The resulting library was 
quantified using Bioanalyzer (Agilent) and Taqman (Life 
Technologies) assays. The barcoded library combined 
was used at a final concentration of 0.4 pM in emulsion 
PCR to link to the sequencing beads.  For analysis, the 
sequencing reads in color-space were mapped to the mm9 
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genome using Tophat [29]. The number of reads falling 
into each gene defined in the RefSeq gene annotations was 
quantified using HTSeq-count [30]. Samples from three 
independent experiments were sequenced, combined, and 
analyzed to produce the final DESeq data. The RNA-Seq 
data is publicly available through the NCBI GEO database 
with accession number GSE61528.
Determination of EC50s and dose response 
analysis
To determine the EC
50
 of crizotinib 2500 cells from 
each clone were plated, in quadruplicate, in a solid white 
cell culture 384-well plate. Crizotinib was added to the 
wells in a three-fold ten-point dilution series ranging from 
12.5 μM to 0.0006 μM. Crizotinib activity was evaluated 
24 hours after treatment using CellTiter-Glo (Promega, 
USA) as a read-out of viability. The EC
50
 values were 
calculated using Graphpad Prism. 
In vivo tumor models and imaging
All animal experiments were approved by the 
Scripps Institutional Animal Care and Use Committee 
and performed in accordance with relevant institutional 
and national guidelines.  The use of the orthotopic tumor 
model was previously described [31]. Briefly, Nf2−/− 
SC4 Schwann cells were transduced by lentiviruses 
carrying pLuc-mCherry and sorted by FACS. 5 × 104 
cells were transplanted into the sciatic nerve sheath 
of NOD/SCID mice (8 weeks of age) by intraneural 
injection. Tumor progression was monitored every 3 
days by bioluminescence imaging (BLI) according to 
the manufacturer’s instructions on an IVIS-200 system 
(Xenogen, San Francisco, CA). 
MIB chromatography
Cells were treated with 10 mM crizotinib for the 
indicated time points and tumors were harvested as 
previously described [16]. Protein lysates containing 
3 mg of total protein each were brought to 1 M NaCl and 
passed through columns of inhibitor-conjugated beads 
(Bisindoylmaleimide-X,SB203580, Dasatinib, PP58, 
VI16832, and CTx-0294885) to isolate protein kinases. 
Kinase-bound inhibitor beads were washed with high- and 
low-salt buffers and 0.1% SDS before elution by boiling in 
0.5% SDS with 1% b-mercaptoethanol in 0.1 M Tris-HCl 
(pH 6.8). Proteins were purified using chloroform/methanol 
extraction and resuspended in 50 mM HEPES (pH 8). 
Samples were digested overnight at 37oC using sequencing 
grade modified trypsin (Promega). Peptides were fractionated 
with Mini SCX spin columns and cleaned with PepClean 
C18 Spin Columns (Thermo Scientific) before MS analysis.
MS analysis
MS and MS/MS data were acquired with a 
Q Exactive™ Hybrid Quadrupole-Orbitrap Mass 
SpectroMETer (Thermo) equipped with an EASY-
nLC1000 nano UHPLC (Thermo). Each individual 
sample was resuspended in 20 mL of sample buffer (2% 
ACN, 0.1% TFA) and injected (5 mL) onto the Thermo 
Scientific EASY-Spray column (C18, 2 mM, 100 A, 
75 mM X 25 cm). A linear gradient from 5% B (CH
3
CN 
+ 0.1% formic acid) to 25% B in 150 minutes and then 
25% B to 45% B in 15 minutes, followed by 45% B to 
95% B in 5 minutes and pumping 95% of B for additional 
10 minutes. MS and MS/MS data were analyzed by 
MaxQuant 1.5.0.0 with a UniProtKB database using label 
free quantifications.  
Statistical analysis
To assess the anti-tumor activity of crizotinib 
in vivo, the natural log-transformed flux readings were 
used to reflect tumor growth. The trends of tumor 
growth over time (followed up by days) were examined 
between control and treatment groups using a mixed-
effect model with the random effect at the mouse 
level.  A linear function, in days, was determined to 
provide the best fit without random slope on follow-
up days.  A likelihood ratio testing nested models 
(with versus without the interaction term of group and 
time) was used to examine if trends are significantly 
different overall between groups. The tumor weights 
were first examined by a Shapiro-Wilk test to assess 
data normality and a Variance ratio test was used to 
examine the equality of variances between two groups. 
The differences between the control and experimental 
cohorts were analyzed by a t-test with equal variances. 
Statistical analyses were performed using Stata 12.0 
(StataCorp LP, Texas, USA).
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